This includes full-scale commercial production capabilities, including dispensing, granulation, compression, film coating and primary packaging. The new area will utilize abatement technology, which is used for the elimination of solvent emissions and meets projected 2020 Ministry of Environment Standards.
The expansion of dedicated space for the production of oral contraceptives, is a regulatory requirement to sell in many countries. By providing dedicated space, Patheon will free up manufacturing capacity in the Toronto facility for current and new commercial business and allow for future growth within the pharmaceutical development services area. The newly expanded Toronto site will be a center of excellence for oral contraceptives under Patheon’s Quick to Clinic program.
Terry Novak, president of North America at Patheon, said: “This expansion positions Patheon to compete on a higher level for contract manufacturing opportunities and claim a larger portion of the global oral contraceptive manufacturing market.”